Vemurafenib Benefits People Previously Treated for Melanoma

A New England Journal of Medicine study found that vemurafenib, which was approved by the FDA in 2011, controlled melanomas in about half of people who had been previously treated for this disease. The trial included 132 repeat patients; tumors shrank in 47% of the patients and were not evident in 6% during the course of the trial. Vemurafenib is a BRAF inhibitor and about half of melanoma patients have BRAF mutations. While 26% of patients developed another kind of skin cancer called squamous cell carcinoma, these lesions were successfully removed surgically.

Primary source: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112302

Leave a Reply

You must be logged in to post a comment.